This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Dermatology				
Scars/wrinkles	Focal adhesion kinase (FAK)	<p>Mouse studies suggest topical FAK inhibitors could help prevent dermal scarring. In a mouse model of cutaneous scarring, a topical FAK inhibitor decreased scar formation compared with vehicle. Next steps include identifying new FAK inhibitors and developing drug-eluting dermal hydrogels.</p> <p>CureFAKtor Pharmaceuticals LLC's FAK and VEGF receptor 3 (FLT4; VEGFR-3) inhibitor, CFAK-C4, is in preclinical development for pancreatic cancer.</p> <p>Teva Pharmaceutical Industries Ltd.'s anaplastic lymphoma kinase (ALK) and FAK inhibitor, CEP-37440, is in preclinical development for multiple cancers.</p> <p>SciBX 5(1); doi:10.1038/scibx.2012.16 Published online Jan. 5, 2012</p>	Patent application filed; available for licensing	<p>Wong, V.W. <i>et al. Nat. Med.</i>; published online Dec. 11, 2011; doi:10.1038/nm.2574</p> <p>Contact: Geoffrey C. Gurtner, Stanford University, Stanford, Calif. e-mail: ggurtner@stanford.edu</p>